Merck’s RSV drug meets key end-stage trial targets
![](https://4gi.tv/wp-content/uploads/2024/07/2407-ws-he1-1024x576.jpg)
Merck said Tuesday that its respiratory syncytial virus (RSV) drug met safety and efficacy targets in a mid- to late-stage study testing it in infants.
ENTRADAS POPULARES
![](https://4gi.tv/wp-content/uploads/2024/09/0609-ws-env2.jpg)
Pope Francis calls for action on climate change
septiembre 6, 2024
![](https://4gi.tv/wp-content/uploads/2024/09/0609-ws-env1.jpg)
Climate change costing Africa up to 5% of GDP, UN says
septiembre 6, 2024
![](https://4gi.tv/wp-content/uploads/2024/09/0609-ws-env.jpg)
A forest fire has destroyed 20% of the forests in Brazil
septiembre 6, 2024
![](https://4gi.tv/wp-content/uploads/2024/09/0609-ws-cul2.jpg)
Toronto Film Festival showcases an industry transformed by streaming
septiembre 6, 2024
TRANSMISIÓN EN VIVO